Table 1.
Clinical information of liver cancer patients with single-cell transcriptome data
| Variable | Longitudinal single-cell cohort (n = 11), no. (%) | Validation single-cell cohort (n = 31), no. (%) |
|---|---|---|
| Age (years)a | ||
| 30–39 | 0 | 2 (6.5) |
| 40–49 | 0 | 3 (9.7) |
| 50–59 | 2 (18.2) | 2 (6.5) |
| 60–69 | 5 (45.5) | 13 (41.9) |
| 70–79 | 3 (27.3) | 8 (25.8) |
| 80+ | 1 (9.1) | 3 (9.7) |
| Gender | ||
| Female | 1 (9.1) | 15 (48.4) |
| Male | 10 (90.9) | 16 (51.6) |
| Etiology | ||
| Fatty liver | 0 | 2 (6.5) |
| HBV | 2 (18.2) | 3 (9.7) |
| HCV | 5 (45.5) | 10 (32.3) |
| HBV + HDV | 1 (9.1) | 0 |
| None | 3 (27.3) | 14 (45.2) |
| No data | 0 | 2 (6.5) |
| Stage | ||
| I | 0 | 2 (6.5) |
| II | 1 (9.1) | 1 (3.2) |
| III | 2 (18.2) | 6 (19.4) |
| IV | 8 (72.7) | 20 (64.5) |
| No data | 0 | 2 (6.5) |
| Diagnosis | ||
| HCC | 9 (81.8) | 20 (64.5) |
| iCCA | 2 (18.2) | 11 (35.5) |
| Treatment | ||
| Pembrolizumab | 1 (9.1) | 5 (16.1) |
| Tremelimumab | 1 (9.1) | 1 (3.2) |
| Tremelimumab + Durvalumab | 8 (72.7) | 16 (51.6) |
| Resection only | 1 (9.1) | 6 (19.4) |
| None | 0 | 3 (9.7) |
| CA19-9 | ||
| ≤35 U/mL | 6 (54.5) | 7 (22.6) |
| >35 U/mL | 5 (45.5) | 11 (35.5) |
| No data | 0 | 13 (41.9) |
| Alpha-fetoprotein | ||
| Negative, ≤20 ng/mL | 5 (45.5) | 11 (35.5) |
| Positive, >20 ng/mL | 6 (54.5) | 13 (41.9) |
| No data | 0 | 7 (22.6) |
a
Age at time of baseline tissue collection used for this study.